Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been given an average rating of “Moderate Buy” by the ten brokerages that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $61.11.

HALO has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $68.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, December 18th. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Finally, Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $9,254,244.56. This trade represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Large investors have recently modified their holdings of the stock. Retirement Systems of Alabama lifted its position in Halozyme Therapeutics by 23.5% during the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after acquiring an additional 74,173 shares in the last quarter. Castellan Group lifted its position in shares of Halozyme Therapeutics by 4.5% during the third quarter. Castellan Group now owns 113,798 shares of the biopharmaceutical company’s stock worth $6,514,000 after purchasing an additional 4,876 shares in the last quarter. Tidal Investments LLC boosted its stake in shares of Halozyme Therapeutics by 265.5% in the third quarter. Tidal Investments LLC now owns 20,576 shares of the biopharmaceutical company’s stock valued at $1,178,000 after purchasing an additional 14,947 shares during the period. World Investment Advisors LLC acquired a new stake in Halozyme Therapeutics during the 3rd quarter valued at $3,293,000. Finally, Sanctuary Advisors LLC increased its stake in Halozyme Therapeutics by 80.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 37,039 shares of the biopharmaceutical company’s stock worth $2,120,000 after buying an additional 16,511 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 0.8 %

Shares of HALO stock opened at $47.54 on Thursday. The company has a market capitalization of $6.05 billion, a price-to-earnings ratio of 15.74, a PEG ratio of 0.43 and a beta of 1.23. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The firm has a 50-day moving average price of $50.65 and a 200 day moving average price of $54.13. Halozyme Therapeutics has a twelve month low of $33.15 and a twelve month high of $65.53.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.